Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nikolaos Botsoglou

Hematology Cheektowaga, NY Medical Doctor

NPI 1225015621 CMS profile 191886

2475 Harlem Rd, Cheektowaga, NY 14225

Open in the dashboard

General payments

$10,375

421 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nikolaos Botsoglou of Cheektowaga, NY is reported in the CMS Open Payments database as having received $10,375 across 421 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107 5
2024 General $248 11
2023 General $1,318 65
2022 General $2,027 82
2021 General $2,364 81
2020 General $1,897 96
2019 General $2,413 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nikolaos Botsoglou
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Nikolaos Botsoglou were reported at $107. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Nikolaos Botsoglou Hematology median Middle half National median
2019 $2,413 $1,012 $122–$9,834 $163
2020 $1,897 $1,475 $115–$9,198 $114
2021 $2,364 $1,470 $125–$7,444 $132
2022 $2,027 $1,371 $139–$8,471 $149
2023 $1,318 $1,295 $147–$11,010 $160
2024 $248 $1,286 $146–$9,230 $164
2025 $107 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,023 85 payments
  2. AbbVie, Inc. $1,808 45 payments
  3. Janssen Biotech, Inc. $932 72 payments
  4. UCB, Inc. $734 35 payments
  5. GlaxoSmithKline, LLC. $638 16 payments
  6. Pfizer Inc. $606 31 payments
  7. E.R. Squibb & Sons, L.L.C. $579 32 payments
  8. Janssen Pharmaceuticals, Inc $461 11 payments
  9. AstraZeneca Pharmaceuticals LP $391 7 payments
  10. Novo Nordisk Inc $389 5 payments
  11. Other $1,815 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,765 418 payments
  2. Consulting Fee $525 1 payment
  3. Education $85 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,262 28 payments
  2. SIMPONI ARIA $842 65 payments
  3. Otezla $803 35 payments
  4. Cimzia $734 35 payments
  5. Enbrel $606 27 payments
  6. ORENCIA $566 31 payments
  7. STELARA $553 40 payments
  8. SIMPONI $494 37 payments
  9. REMICADE $480 36 payments
  10. XARELTO $456 10 payments
  11. Other $5,972 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

421 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record